Group 1 - The core viewpoint of the article is that Sairun Biotech (688163.SH) has not included its products in the national drug procurement led by the National Healthcare Security Administration [1] - The company currently has no plans to adjust the price of its anti-snake venom serum [1] - The anti-snake venom serum plays a crucial role in quickly neutralizing toxins, reducing harm to patients, shortening recovery time, improving prognosis, and decreasing treatment costs for complications caused by poisoning [1] Group 2 - The article highlights that with ongoing social progress and an increase in public health awareness and demand, the construction of a snakebite treatment system is expected to improve [1] - The key role and usage principles of anti-snake venom serum are anticipated to receive more attention and implementation in clinical settings [1]

Group 1 - A total of 155 stocks in the Shanghai and Shenzhen markets have experienced net financing inflows for 5 consecutive days or more as of August 11 [1] - The stock with the longest consecutive net inflow is Huicheng Environmental Protection, which has seen net inflows for 21 trading days [1] - Other notable stocks with significant consecutive net inflows include China High-Tech, Taijing Technology, Sailun Biology, Tanshan Explorer, Hengsheng Electronics, Three Gorges New Materials, New Jingang, and Limin Co., which have all recorded net inflows for 12 or 11 trading days respectively [1]

证券代码：688163 证券简称：赛伦生物 公告编号：2025-019 上海赛伦生物技术股份有限公司2025年第一次临时股东大会决议公告 本公司董事会及全体董事保证公告内容不存在任何虚假记载、误导性陈述或者重大遗漏，并对其内容的 真实性、准确性和完整性依法承担法律责任。 重要内容提示： ● 本次会议是否有被否决议案：无 一、会议召开和出席情况 （一）股东大会召开的时间：2025年8月11日 （二）股东大会召开的地点：上海赛伦生物技术股份有限公司（上海市青浦区 华青路1288号）会议室 （三）出席会议的普通股股东、特别表决权股东、恢复表决权的优先股股东及其持有表决权数量的情 况： ■ （四）表决方式是否符合《公司法》及公司章程的规定，大会主持情况等。 本次股东大会由公司董事会召集，董事长范志和先生主持。本次股东大会以现场方式召开，采用现场投 票与网络投票相结合的方式表决。会议的召集、召开及表决方式符合《公司法》《公司章程》的规定， 会议决议合法、有效。 （五）公司董事、监事和董事会秘书的出席情况 1、公司在任董事9人，出席9人； 2、公司在任监事3人，出席3人； 表决情况： ■ 3、董事会秘书成琼女士现场出席了 ...

证券日报网讯 8月11日晚间，赛伦生物发布公告称，公司2025年第一次临时股东大会于2025年8月11日 召开，审议通过了《关于修订和制定公司部分治理制度的议案》等。 （文章来源：证券日报） ...

证券代码：688163 证券简称：赛伦生物 公告编号：2025-019 上海赛伦生物技术股份有限公司 2025年第一次临时股东大会决议公告 本公司董事会及全体董事保证公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 本次会议是否有被否决议案：无 （五） 公司董事、监事和董事会秘书的出席情况 1、 公司在任董事9人，出席9人； 2、 公司在任监事3人，出席3人； 一、 会议召开和出席情况 （一） 股东大会召开的时间：2025 年 8 月 11 日 （二） 股东大会召开的地点：上海赛伦生物技术股份有限公司（上海市青浦区 华青路 1288 号）会议室 （三） 出席会议的普通股股东、特别表决权股东、恢复表决权的优先股股东及 其持有表决权数量的情况： | 1、出席会议的股东和代理人人数 | 76 | | --- | --- | | 普通股股东人数 | 76 | | 2、出席会议的股东所持有的表决权数量 | 65,880,183 | | 普通股股东所持有表决权数量 | 65,880,183 | | 3、出席会议的股东所持有表决权数量占公司表决权数量 ...

上海市锦天城律师事务所 关于上海赛伦生物技术股份有限公司 2025 年第一次临时股东大会的 法律意见书 地址：上海市浦东新区银城中路 501 号上海中心大厦 9/11/12 层 电话：021-20511000 传真：021-20511999 邮编：200120 上海市锦天城律师事务所 法律意见书 上海市锦天城律师事务所 关于上海赛伦生物技术股份有限公司 2025 年第一次临时股东大会的法律意见书 致：上海赛伦生物技术股份有限公司 上海赛伦生物技术股份有限公司（以下简称"公司"）2025 年第一次临时股 东大会（下称"本次股东大会"或"会议"）于 2025 年 8 月 11 日在公司会议室召 开。上海市锦天城律师事务所（下称"本所"）经公司董事会聘请，委派吕希菁、 付慧琪律师（下称"经办律师"）出席会议，根据《中华人民共和国证券法》（以 下简称"《证券法》"）、《中华人民共和国公司法》（以下简称"《公司法》"）、 《上市公司股东会规则》（以下简称"《规则》"）和《上海赛伦生物技术股份有 限公司章程》（以下简称"《公司章程》"）的规定，就本次股东大会的召集和召 开程序、出席会议人员资格、召集人的资格、会议的表决程 ...

Core Insights - As of August 8, a total of 160 stocks in the Shanghai and Shenzhen markets have experienced net financing inflows for five consecutive days or more [1] - The stock with the longest consecutive net inflow is Huicheng Environmental, which has seen net buying for 20 trading days [1] - Other notable stocks with significant consecutive net inflows include China Baowu, Jichuan Pharmaceutical, Taijing Technology, Sairun Bio, Tanshan, Hengsheng Electronics, China High-Tech, Xinjin Steel, Limin Co., and CIMC Vehicles, with net inflows for 14, 13, 11, 11, 11, 11, 11, 10, 10, and 10 trading days respectively [1]

Core Insights - As of August 7, a total of 143 stocks in the Shanghai and Shenzhen markets have experienced net financing inflows for five consecutive days or more [1] - The stock with the longest consecutive net inflow is Huicheng Environmental, which has seen net buying for 19 trading days [1] Summary by Related Categories Stocks with Significant Net Inflows - Huicheng Environmental has the highest consecutive net inflow days at 19 [1] - Other notable stocks with substantial net inflow days include: - China Baowu Steel with 13 days [1] - Jichuan Pharmaceutical with 12 days [1] - Tianzhihang, Zhejiang Communications, and China High-Tech each with 11 days [1] - Haizheng Pharmaceutical, Caixun Technology, Taijing Technology, Sailun Biotech, and Tanjia with 10 days each [1]

Group 1 - The company, Siron Biotech (688163.SH), has stated on its interactive platform that it has not conducted any research related to HIV vaccines [1]

Market Overview - The biopharmaceutical sector increased by 0.55% on August 4, with Sairun Biotech leading the gains [1] - The Shanghai Composite Index closed at 3583.31, up 0.66%, while the Shenzhen Component Index closed at 11041.56, up 0.46% [1] Top Gainers in Biopharmaceutical Sector - Sairun Biotech (688163) closed at 27.37, up 11.90% with a trading volume of 72,700 shares and a transaction value of 190 million [1] - Xizang Pharmaceutical (600211) closed at 46.19, up 10.00% with a trading volume of 321,400 shares and a transaction value of 1.451 billion [1] - Wanze Shares (000534) closed at 17.31, up 9.97% with a trading volume of 598,100 shares and a transaction value of 1.018 billion [1] - Other notable gainers include Saiseng Pharmaceutical (300485) and Sanyuan Gene (837344) with increases of 7.45% and 6.89% respectively [1] Top Losers in Biopharmaceutical Sector - Kexing Pharmaceutical (688136) closed at 50.20, down 9.42% with a trading volume of 129,900 shares and a transaction value of 655 million [2] - Aopumai (688293) closed at 57.00, down 6.56% with a trading volume of 20,800 shares and a transaction value of 119 million [2] - Other significant decliners include Wuxi Jinghai (836547) and Olin Biotech (688319) with decreases of 3.28% and 3.22% respectively [2] Capital Flow Analysis - The biopharmaceutical sector saw a net inflow of 10.35 million from institutional investors, while retail investors contributed a net inflow of 250 million [2][3] - Notable net inflows from individual stocks include Ganjin Pharmaceutical (603087) with 18.6 million and Xizang Pharmaceutical (600211) with 12.1 million [3] - Conversely, significant net outflows were observed in stocks like Xizang Pharmaceutical and Wanze Shares, indicating a mixed sentiment among retail investors [3]